Quest Diagnostics has introduced a new blood test aimed at assisting physicians in confirming amyloid brain pathology related ...

Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 months in early ...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help ...